Novartis Sells Eye Drugs to Bausch + Lomb for Up to $2 5 Billion bloomberg.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bloomberg.com Daily Mail and Mail on Sunday newspapers.
Bausch + Lomb to buy dry eye treatment from Novartis in a $2 5 billion deal marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.
(Reuters) -Bausch + Lomb Corp will purchase a dry-eye drug from Swiss pharma company Novartis for $1.75 billion, the Wall Street Journal reported on F.
Eye healthcare firm Bausch + Lomb Corp. (BLCO) Friday said it has entered into a definitive agreement to buy XIIDRA (lifitegrast ophthalmic solution) 5%, a non-steroid eye drop, from Swiss drug major Novartis AG (NVS) for up to $2.